Dr. Sanjay Kalra
Future of Diabetes...What next for Gliptins
Dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, are a relatively new class of oral drugs for type 2 diabetes. These drugs block the DPP-4 enzyme metabolism of incretin hormones, including GLP-1 and GIP. In this issue of Diabetes News Nucleus, let us understand more about gliptins and the future of diabetes management with special focus on this new class of drugs.
Dr. Sanjay Kalra
Dr. Sanjay Kalra is a globally recognized endocrinologist with extensive contributions to clinical care, research, and medical education. He currently serves as the Treasurer of the International Society of Endocrinology (ISE) and President of the Association of Longevity and Anti-ageing Medicine. He has previously held leadership positions as President of the Endocrine Society of India (ESI), South Asian Federation of Endocrine Societies (SAFES), and the Indian Professional Association for Transgender Health (IPATH). With a strong academic and research background, Dr. Kalra has served as Principal Investigator in over 50 international Phase 1–4 clinical trials. He is also the Principal Investigator for Haryana in the Indian Council of Medical Research’s INDIAB study. A prolific speaker, Dr. Kalra has delivered more than 1000 lectures on diverse endocrinology topics across five continents, including Europe, North America, Africa, Asia, and Australia.
More FAQs by Dr. Sanjay Kalra
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article